Fig. 8

Recombinant dU-TG2P potentiated DC-mediated tumor therapy. a dU-TG2P enhances DC cell spreading on Fn. WT DCs treated with dU-TG2P (10 µM) were placed on Fn-coated plates, and the spreading area was measured using ImageJ. Scale bar, 10 μm. b–d OTII CD4⁺ T cells were co-incubated with nothing or with dU-TG2P-treated WT DCs pulsed with pOVA (323–339), and then, the cells or cultured supernatants were subjected to a conjugate assay (b), cytokine production assessment (c), and proliferation test (d). e, f Gross images of OVA⁺B16F10 lung and solid tumors, respectively. C57BL/6 mice were injected i.v. with media alone, DCs, or dU-TG2P-treated DCs pulsed with pOVA (257–264). After 7 days, the mice were i.v. (e) or s.c. (f) injected with OVA⁺B16F10 cells. The metastatic nodules (e) and tumor sizes and weights (f) were measured after 8 days of OVA⁺B16F10 injection. g The survival rates of tumor-bearing mice post-implantation are shown. All data represent the mean of three experiments ± SEM. *P < 0.01